Skin pigmentation and vitamin D synthesis: clinical nuances

It is tidy, emotive, and almost entirely wrong about the magnitude of the effect.

Cutaneous vitamin D synthesis is a photochemical reaction, and like every photochemical reaction it obeys a set of measurable variables. Skin pigment is one of them. Latitude, baseline serum status, exposed surface area, season, clothing, sunscreen use, and behaviour are the others. The uncomfortable biochemical reality is that melanin is a filter, not a wall. It changes the dose required for a given response, but it does not switch the pathway off.

That distinction matters in clinical practice and in population-health planning. A fortification programme built around the assumption that skin colour alone predicts vitamin D status will miss the stronger determinants of deficiency. So will a consultation that treats pigmentation as a diagnosis rather than one variable in a larger exposure equation.

Melanin as an Endogenous Optical Filter: The Physics of UVB Absorption

Every time a photon in the 290–320 nm ultraviolet B (UVB) range strikes the epidermis, it encounters several possible molecular destinations. One is 7-dehydrocholesterol, or 7-DHC, stored in the plasma membranes of keratinocytes. Others include the chromophores of melanin, concentrated in melanosomes.

Cutaneous vitamin D3 synthesis begins when a UVB photon reaches a 7-DHC molecule and opens its B-ring, producing previtamin D3. That molecule then undergoes thermal isomerisation to vitamin D3 over the following period, commonly described as roughly 24–48 hours. The first requirement is therefore simple but unforgiving: enough of the relevant UVB radiation must reach enough 7-DHC.

Melanin absorbs UVB before it reaches that precursor pool. It is a broadband optical absorber, not a binary barrier. More epidermal melanin means that a larger share of incoming photons is intercepted or scattered before the photochemical reaction can occur. The result is lower conversion efficiency per unit of incident UVB.

Fitzpatrick's 1975 phototype classification is often used as a clinical proxy for this difference in optical density. Types I and II generally represent skin that burns readily and tans little or minimally. Types V and VI represent skin with greater constitutive pigmentation and a much lower tendency to burn. The scale is useful, but it is not a spectrophotometer and it should not be treated as a precise biological measurement. People within the same category can differ in pigment distribution, tanning history, sun behaviour, and response to exposure.

The key point survives that limitation. Melanin attenuates UVB; it does not abolish the reaction. Even at Fitzpatrick type VI, suberythemal UVB doses can photolyse 7-DHC. The reaction may require a greater incident dose to produce the same output, but the photons are not refused entry.

This is the first myth worth dismantling: dark skin does not block vitamin D synthesis. It reduces the efficiency of the conversion. That distinction is the difference between a clinical fact and a marketing soundbite.

The phrase “skin pigmentation and vitamin D synthesis efficiency” is therefore more accurate than the familiar claim that one group can make vitamin D and another cannot. Efficiency is the issue. The clinical question is how that difference interacts with location, season, body surface area, and starting vitamin D status.

Quantifying the Inhibition Factor: Comparing Fitzpatrick Types II and VI

If the filter hypothesis is put to a controlled test, what magnitude of effect does melanin actually produce?

The clearest comparison in the available evidence comes from studies that exposed the extreme phenotypes—Fitzpatrick type II and type VI—to identical suberythemal UVB doses and measured the resulting change in vitamin D3. Young and colleagues, publishing in the Journal of Investigative Dermatology in mid-2020, reported inhibition factors of roughly 1.3 to 1.4 between these phenotypes.

In practical terms, that means the higher-pigment group produced approximately 70–77% of the vitamin D3 produced by the lower-pigment group under the same experimental UVB exposure. The result is not negligible. It is also not the order-of-magnitude gap suggested by some commercial narratives.

Melanin reduces UV photo-conversion efficiency by a small-to-moderate factor—about 1.3 to 1.4× in the documented Fitzpatrick type II–VI comparison. It is a filter, not a wall.

The wording matters because an inhibition factor derived from an extreme type II–VI comparison cannot automatically be assigned to Fitzpatrick type V. Type V is not a shorthand for type VI, and the numerical relationship between phototypes should not be filled in by intuition. A type V individual may have substantial epidermal melanin and may require more UVB than a type II individual under comparable conditions, but the specific 1.3–1.4 factor is not established here as a type V value.

That limitation does not weaken the broader conclusion. It makes the conclusion more disciplined. We can distinguish between a measured comparison and a plausible clinical inference without turning the latter into a false number.

A 1.3–1.4× inhibition factor is clinically meaningful, but it does not describe an immovable physiological deficit. A person can alter the effective dose by changing the amount of skin exposed, the duration of exposure, or the timing of exposure. The size of the adjustment depends on latitude, season, cloud cover, clothing, and the risk of erythema. There is no universal conversion table in which one Fitzpatrick category maps neatly to one fixed number of minutes.

The Bogh et al. baseline study, conducted earlier, had already established another important part of the equation: the serum vitamin D response to UVB depends heavily on the starting concentration of 25-hydroxyvitamin D, or 25(OH)D. Two people with similar pigmentation and similar exposure can show different serum responses because they begin the season with different reserves, have different dietary intake, or differ in body composition and metabolism.

The mechanism is straightforward. Photon delivery is necessary, but it is not the entire clinical story. The amount of UVB reaching 7-DHC, the available precursor, the skin area exposed, and the patient's baseline status all influence the measured result.

What the comparison does—and does not—show

The controlled type II–VI comparison supports three modest conclusions:

• Higher epidermal melanin can reduce vitamin D photoconversion under the same UVB conditions.
• The reduction is measurable without implying that synthesis has stopped.
• A numerical inhibition factor should remain attached to the phototypes and experimental conditions in which it was documented.

It does not support a universal claim that every person with type V or VI skin requires exactly the same multiple of exposure. Nor does it establish that skin colour is the best predictor of an individual's serum 25(OH)D concentration. Those are separate questions, and they require different evidence.

Latitude and Exposure Dynamics: Modeling Requirements for Darker Skin Phenotypes

The variable that often dominates the equation is not melanin. It is the solar zenith angle at the location where the skin in question lives.

UVB flux at the Earth's surface depends on latitude, season, time of day, ozone, cloud cover, altitude, and the geometry of the exposure. At higher latitudes, the sun remains lower in the sky for more of the year, and the atmosphere filters a larger proportion of the relevant short-wave radiation. The result is a seasonal window in which outdoor light may be plentiful while vitamin-D-producing UVB remains limited.

A melanin-rich individual living near the equator therefore has a very different vitamin D forecast from a melanin-poor individual living at 55° north. Geography can outweigh phenotype. The same skin exposed for the same duration does not receive the same biologically effective UVB dose in both places.

Modeling work for UK latitudes provides a concrete illustration. In that setting, UVB is only meaningfully available for cutaneous vitamin D production during part of the year, roughly from March through September. Fitzpatrick type V adults exposing the forearms and lower legs around lunchtime across that period may require approximately 25 minutes of daily exposure under typical UK summer conditions to meet modeled vitamin D requirements. A fair-skinned type II adult under the same broad model requires less exposure.

Standard reference recommendations for type II skin put the requirement at roughly 0.5 minimal erythemal dose (MED) two to three times per week, which translates to about 12 minutes under a high UV index of 7. These figures are model outputs, not promises. They depend on the assumed surface area, clothing, season, solar angle, atmospheric conditions, and the definition of an adequate vitamin D response.

The original comparison between types II and VI should not be repurposed as a type V coefficient. The table below keeps the measured inhibition factor in its proper place and separates it from the type V exposure model.

The table is not showing that type V individuals are physiologically incapable of cutaneous synthesis. It is showing that the same modeled outcome may require a longer exposure window or a larger exposed surface area. It is also showing why a model-specific exposure estimate should not be mistaken for a general law of pigmentation.

There is a second safety issue here. “Suberythemal” does not mean biologically harmless. Avoiding visible sunburn is not the same as eliminating cumulative ultraviolet damage. Increasing exposure time to compensate for melanin must not become an argument for prolonged tanning or deliberate burning. The useful question is not how much sun a person can tolerate, but how to obtain an appropriate biological dose without converting a vitamin D discussion into a skin-cancer risk discussion conducted too late.

Latitude changes the UVB dose before skin colour enters the calculation. A phototype is not a location, a season, or a behaviour pattern.

In practical modeling, exposed surface area is often underappreciated. A short-sleeved person outdoors with forearms and lower legs uncovered may receive a very different dose from someone whose face and hands are the only exposed sites. Clothing can dominate the calculation even when the two people have identical pigmentation. The same is true of timing: morning and late-afternoon light may feel bright while delivering less vitamin-D-effective UVB than a shorter exposure nearer solar noon.

The clinically responsible language is therefore conditional: darker skin may need a greater UVB dose for the same cutaneous response, but the required dose varies with the environment and the way exposure occurs.

Beyond Pigmentation: Why Baseline Status and Behaviour Outweigh Skin Colour

This is where the supplement lobby and the dermatology lobby have often argued past each other. The dominant driver of hypovitaminosis D in any population is rarely skin pigment alone. It is the combined effect of baseline serum 25(OH)D, dietary intake, supplementation, indoor-versus-outdoor occupation, clothing coverage, sunscreen use, adiposity, age, season, and latitude.

None of these variables is visible at the level of melanin density.

Adipose tissue can sequester vitamin D, making body composition relevant to circulating availability. Age-related changes in the skin can reduce the availability of 7-DHC. A person who spends the working day indoors may receive little effective UVB even in a sunny climate. Someone who covers most of the body for cultural, occupational, or weather-related reasons may have a much smaller exposed surface area. Sunscreen, when applied correctly and consistently, reduces UVB transmission to the skin. Diet and supplements can partly bypass the cutaneous pathway altogether.

This is the second myth worth dismantling: that dark skin is the explanation. In the UK and northern Europe, type V and type VI populations may show lower mean serum 25(OH)D than type I–II populations on average. But group averages do not identify the cause in an individual, and the variation within each pigmentation group can be substantial.

A type II office worker in Manchester with an indoor lifestyle, low dietary intake, and high body mass index may finish the winter with worse serum status than a type V outdoor worker in Birmingham whose working day includes regular time outside. That example is not a claim about every worker in either city. It demonstrates the structure of the problem: phenotype is one input, not destiny.

The most useful clinical history is consequently more detailed than a visual assessment:

• Where does the patient live, and what season is it?
• How much time is spent outdoors during periods when UVB is biologically relevant?
• Which parts of the body are normally uncovered?
• Does clothing or occupational equipment limit exposure?
• Is sunscreen used routinely, occasionally, or not at all?
• What is the dietary pattern, and is vitamin D supplementation already being taken?
• Are age, body composition, malabsorption, or other medical factors likely to affect vitamin D status?
• Was the 25(OH)D measurement taken after a period of low winter exposure or after supplementation had begun?

These questions do not make skin pigmentation irrelevant. They place it in the correct position. Pigmentation can modify the dose required, while behaviour determines whether that dose is ever received.

This distinction is especially important for population-health policy. A programme that labels dark-skinned communities as uniquely deficient may identify a real disparity while misdescribing its causes. The disparity may reflect latitude, migration from high-UVB regions into low-UVB environments, clothing, occupational patterns, dietary access, reduced outdoor time, or limited access to fortified foods and clinical testing. Skin colour may be correlated with several of these factors without being the mechanism that explains all of them.

The same problem appears when supplementation is presented as the only rational response. Supplementation can be clinically appropriate, particularly during low-UVB months or when deficiency has been documented. But a fortification programme must still consider the whole population. People with lighter skin can also spend most of their time indoors, avoid midday exposure, cover their skin, or begin winter with low serum stores.

If advice is targeted only by appearance, it becomes both less accurate and less fair. Public-health interventions should be weighted by measured prevalence, dietary patterns, seasonality, and access—not by an assumption that melanin determines serum status.

Clinical Thresholds and the Reality of Cutaneous Vitamin D Production

The endpoint of this photochemistry is serum 25-hydroxyvitamin D, the circulating reserve metabolite measured in clinical practice. Thresholds are not perfectly interchangeable across laboratories or organizations, but two reference points are commonly used in population-health discussions.

The first defines vitamin D deficiency as serum 25(OH)D below 12 ng/mL, or 30 nmol/L. The second places the lower bound for bone-health adequacy at 20 ng/mL, or 50 nmol/L, and above. These thresholds describe serum status; they do not tell us whether the missing vitamin D came from insufficient UVB, inadequate intake, altered metabolism, or several causes acting together.

Cutaneous synthesis has a built-in ceiling. Previtamin D3 itself absorbs UVB and undergoes photoisomerisation into inactive photoproducts once a critical dose is reached. Extended sunbathing therefore does not increase serum vitamin D indefinitely. After a point, additional exposure produces diminishing returns and adds ultraviolet damage without offering a proportional biochemical benefit.

This is the third myth worth dismantling: more sun does not always equal more vitamin D. Photodegradation limits previtamin D3 accumulation regardless of skin colour. Darker skin shifts the dose-response relationship, but it does not remove the ceiling. Lighter skin reaches the photochemical limit more quickly, but that does not make excessive exposure desirable.

There is also a distinction between the skin reaction and the serum measurement. A person may produce vitamin D in the skin while still having a low circulating 25(OH)D concentration if exposure is intermittent, the exposed area is small, the season is unfavorable, or the starting level is very low. Conversely, adequate serum status may reflect fortified foods or supplements rather than recent sunlight. Serum 25(OH)D is an integrated marker, not a direct readout of how efficiently the skin performed on a particular afternoon.

Putting the two halves together—the inhibition factor and the photodegradation ceiling—gives a coherent clinical picture. Melanin attenuates UVB before it reaches 7-DHC. The remaining photons still drive synthesis, but the dose-response is shallower. The ceiling is set by photochemistry, not ethnicity. The floor is set by exposure, diet, baseline status, and physiology, not ethnicity either.

What this means for fortification research

For a scientific research project on food fortification with vitamin D, pigmentation should be treated as a stratification variable rather than a complete explanation. A study that compares fortified-food intake with serum outcomes should record phototype, latitude, season, outdoor exposure, clothing, supplement use, body composition, and baseline 25(OH)D. Without those variables, a difference between groups can be attributed to melanin when it may actually reflect exposure or diet.

The same principle applies to intervention design. If a population has limited UVB exposure during winter, fortification can provide a more predictable source than attempting to engineer safe sunlight exposure. If the problem is low baseline status in a subgroup, the programme may need targeted distribution or clinical follow-up rather than a message about skin colour. If the main barrier is dietary access, a fortification strategy should address the food vehicles people actually consume.

The biological pathway is specific. The public-health response does not have to be.

The Verdict From the Bench

Skin pigmentation is a measurable optical variable in the cutaneous vitamin D equation. The documented inhibition factor between Fitzpatrick type II and type VI is roughly 1.3–1.4× under controlled suberythemal UVB exposure. That is real and should inform exposure guidance for higher phototypes: more time may be required, a larger surface area may matter, and the exposure window may need to coincide with periods of stronger UVB.

But that number should not be reassigned to type V without evidence. A type V exposure model can indicate a longer modeled requirement at UK latitudes, yet that is not the same thing as a measured type V inhibition factor. Keeping those claims separate is not pedantry. It is the difference between evidence-based interpretation and numerical overreach.

Pigmentation is also not the dominant driver of population-level hypovitaminosis D. Latitude, season, baseline 25(OH)D, outdoor behaviour, clothing, diet, supplementation, age, and body composition can outweigh the pigment effect in real patients. Skin colour can signal a need to ask better questions, but it cannot answer those questions by itself.

If you are designing a fortification programme or a public-health campaign, the evidence points toward latitude-appropriate nutrition, attention to low-UVB months, baseline-status assessment where clinically justified, and dietary or supplemental coverage applied across phototypes. The weighting should follow measured prevalence and actual exposure patterns, not skin-colour assumptions.

If you are a clinician looking at a patient with low 25(OH)D, measure the serum status before assigning a cause. Ask about exposure, diet, clothing, supplementation, season, and medical context. Melanin changes the optical filter. It does not write the entire clinical history.